PITTSBURGH (April 28, 2020) …
The University of Pittsburgh’s Center for Medical Innovation (CMI) has awarded a
$15,000 grant through an “expedited” 2020 Round-1 Pilot Funding Program for
Early Stage Medical Technology Research and Development. The one-year award
starting May 1, 2020 was granted in response to a request for proposal (RFP) for
projects with an immediate impact on the COVID-19 pandemic. The project
co-investigators are Dr. David Turer, MD (Department of Plastic Surgery, UPMC),
Dr. Heng Ban, PhD (Professor of Mechanical Engineering and Materials Sciences,
Swanson School of Engineering), and Dr. J. Peter Rubin, MD (Chairman, Plastic
Surgery, UPMC). The project title is “Individual
Biocontainment Unit for Reducing Viral Transmission to Healthcare Workers and
Patients”. The IBU is a device which brings a new level of portable
contamination protection for health care workers and for other patients in intensive
care facilities.
CMI,
a University Center housed in Pitt’s Swanson School of Engineering (SSOE),
supports applied technology projects in the early stages of development with
“kick-start” funding toward the goal of transitioning the research to clinical
adoption. Proposals are evaluated on the basis of scientific merit, technical
and clinical relevance, potential health care impact and significance,
experience of the investigators, and potential in obtaining further financial investment
to translate the particular solution to healthcare.
“This
is our ninth year of pilot funding, and our leadership team could not be more
excited with the breadth and depth of this round’s awardees,” said Alan D.
Hirschman, PhD, CMI Executive Director. “This early-stage interdisciplinary
research helps to develop highly specific biomedical technologies through a
proven strategy of linking UPMC’s clinicians and surgeons with the Swanson
School’s engineering faculty.”
About the University of Pittsburgh
Center for Medical Innovation
The
Center for Medical Innovation is a collaboration among the Swanson School of
Engineering, the Clinical and Translational Science Institute (CTSI), the
Innovation Institute, and the Coulter Translational Research Partnership II
(CTRP). CMI was established in 2012 to promote the application and development
of innovative biomedical technologies to clinical problems; to educate
the next generation of innovators in cooperation with the schools of
Engineering, Health Sciences, Business, and Law; and to facilitate the
translation of innovative biomedical technologies into marketable products and
services. Over 70 early-stage projects have been supported by CMI with a total
investment of over $1.4 million since inception.
4/28/2020